Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give Up $175 Million in Profits
Linked as:
Summary
SILVER SPRING, Md., May 24 /PRNewswire-USNewswire/ -- Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its Allston, Mass., manufacturing facility and will turn over to the federal government $175 million in unlawful profits from the sale of products that were made at the plant, the U.S. Food and Drug Administration announced today.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)See the full content of this document
Extract
Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give Up $175 Million in Profits
Under the consent decree of permanent injunction, the Cambridge, Mass.-based company agreed to adhere to a strict timetable to bring the plant in line with the reg...
See the full content of this document
Sponsored links
